Roche has claimed the exclusive international rights to Freenome’s multiomic cancer screening approaches, toward the goal of developing blood testing kits for markets outside the U.S. The licensing deal between…
Roche may have been exploring ways to shuttle drugs to the brain for well over a decade, but that’s not stopping the pharma from handing $55 million to Manifold Bio…
Roche has headed back to China to pen a licensing deal worth more than $1 billion biobucks for the rights to a clinical-stage bispecific antibody for respiratory diseases. The asset…
Roche has dropped five Chugai candidates from its clinical pipeline, echoing actions the Japanese business took earlier this year. Chugai revealed (PDF) the suspension of in-house development of the drug…
Roche is forging ahead with plans to seek approval for an eye disease drug candidate despite missing the primary endpoint in one of its phase 3 trials. The Swiss drugmaker…
Roche’s giredestrant was shown to reduce the risk of breast cancer progression or death by 62% for a specific cohort of a phase 3 trial, as the pharma plans for…
Roche, which currently has investigational Alzheimer’s disease drug trontinemab in phase 3 trials, has secured FDA clearance of its blood-based biomarker test for the condition. The minimally invasive Elecsys pTau181…